These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37303137)

  • 1. The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.
    Borralleras C; Castrodeza Sanz J; Arrazola P; Cámara Hijón C; Eiros JM; Castrodeza Sanz J; Arrazola P; Cámara Hijón C; Fernández-Prada M; Gil de Miguel A; Mirada Masip G; Moraga-Llop F; Ocaña Rodríguez D; Puig-Barberà J; Vázquez J; Vergara-Alert J; de Cambra S
    Rev Esp Quimioter; 2023 Oct; 36(5):507-515. PubMed ID: 37303137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
    Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
    Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates.
    Prenafeta A; Bech-Sàbat G; Moros A; Barreiro A; Fernández A; Cañete M; Roca M; González-González L; Garriga C; Confais J; Toussenot M; Contamin H; Pizzorno A; Rosa-Calatrava M; Pradenas E; Marfil S; Blanco J; Rica PC; Sisteré-Oró M; Meyerhans A; Lorca C; Segalés J; Prat T; March R; Ferrer L
    iScience; 2023 Jul; 26(7):107224. PubMed ID: 37502366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Moros A; Prenafeta A; Barreiro A; Perozo E; Fernández A; Cañete M; González L; Garriga C; Pradenas E; Marfil S; Blanco J; Cebollada Rica P; Sisteré-Oró M; Meyerhans A; Prat Cabañas T; March R; Ferrer L
    Vaccine; 2023 Aug; 41(35):5072-5078. PubMed ID: 37460353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
    Barreiro A; Prenafeta A; Bech-Sabat G; Roca M; Perozo Mur E; March R; González-González L; Madrenas L; Corominas J; Fernández A; Moros A; Cañete M; Molas M; Pentinat-Pelegrin T; Panosa C; Moreno A; Puigvert Molas E; Pol Vilarrassa E; Palmada J; Garriga C; Prat Cabañas T; Iglesias-Fernández J; Vergara-Alert J; Lorca-Oró C; Roca N; Fernández-Bastit L; Rodon J; Pérez M; Segalés J; Pradenas E; Marfil S; Trinité B; Ortiz R; Clotet B; Blanco J; Díaz Pedroza J; Ampudia Carrasco R; Rosales Salgado Y; Loubat-Casanovas J; Capdevila Larripa S; Prado JG; Barretina J; Sisteré-Oró M; Cebollada Rica P; Meyerhans A; Ferrer L
    iScience; 2023 Mar; 26(3):106126. PubMed ID: 36748086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
    Leal L; Pich J; Ferrer L; Nava J; Martí-Lluch R; Esteban I; Pradenas E; Raïch-Regué D; Prenafeta A; Escobar K; Pastor C; Ribas-Aulinas M; Trinitè B; Muñoz-Basagoiti J; Domenech G; Clotet B; Corominas J; Corpes-Comes A; Garriga C; Barreiro A; Izquierdo-Useros N; Arnaiz JA; Soriano A; Ríos J; Nadal M; Plana M; Blanco J; Prat T; Torroella E; Ramos R;
    NPJ Vaccines; 2023 Sep; 8(1):147. PubMed ID: 37775521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
    Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants.
    Damasceno DHP; Amaral AA; Silva CA; Simões E Silva AC
    Curr Med Chem; 2022; 29(15):2673-2690. PubMed ID: 34473613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
    Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
    Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
    Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ
    Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.
    Ralise AEG; Camargo TM; Marson FAL
    Hum Vaccin Immunother; 2023 Aug; 19(2):2234784. PubMed ID: 37449956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.